Publications by authors named "Aderemi Caleb Aladeokin"
Article Synopsis
- l-DOPA is the primary treatment for Parkinson's disease (PD), traditionally thought to work by converting to dopamine.
- Recent research suggests that l-DOPA may actually function as a neurotransmitter.
- The GPR143 receptor, found in both central and peripheral nervous systems and present in PD-associated Lewy bodies, could play a role in how l-DOPA helps treat PD and may also be linked to the disease's progression.*
Alzheimer's disease (AD) is an incurable neurodegenerative disease characterized by memory loss and neurotoxic amyloid beta (Aβ) plaques accumulation. Numerous pharmacological interventions targeting Aβ plaques accumulation have failed to alleviate AD. Also, the pathological alterations in AD start years before the onset of clinical symptoms.
View Article and Find Full Text PDFBlood pressure is regulated by extrinsic factors including noradrenaline, the sympathetic neurotransmitter that controls cardiovascular functions through adrenergic receptors. However, the fine-tuning system of noradrenaline signaling is relatively unknown. We here show that l-3,4-dihydroxyphenylalanine (L-DOPA), a precursor of catecholamines, sensitizes the vascular adrenergic receptor alpha1 (ADRA1) through activation of L-DOPA receptor GPR143.
View Article and Find Full Text PDFAim Of The Study: The extract of the leaves of Alchornea cordifolia (AC) is extensively used in ethnomedicine for ulcers, rheumatic pains, febrile convulsions and for enhancing physical performance. In this study, the anti-stress and anticonvulsant activities of the aqueous leaf extract of Alchornea cordifolia were investigated in mice.
Materials And Methods: The anti-stress activity was assessed based on the ability of the extract to alter the duration of immobility, in the forced swim endurance test, whilst a picrotoxin-treated animal, was employed as the model for convulsive seizures.